Stock comparison
Apellis Pharmaceuticals
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
APLS
Apellis Pharmaceuticals
Market cap
$5.25B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | APLS | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 77B | LMAT |
| Benjamin Graham | 79D | 89A | LMAT |
| Philip Fisher | 71C | 81C | LMAT |
| Peter Lynch | 81C | 67B | APLS |
| Joel Greenblatt | 63C | 56D | APLS |
| Charlie Munger | 67D | 68D | LMAT |
| Terry Smith | 65B | 69D | LMAT |
Side-by-side metrics
| Metric | APLS | LMAT |
|---|---|---|
| Market cap | $5.25B | $2.23B |
| P/E (TTM) | 38.8x | 37.1x |
| EV/EBIT | 96.0x | 36.6x |
| ROIC (TTM) | 18.11% | 9.43% |
| Gross margin | 90.12% | 72.39% |
| Net margin | 12.06% | 24.35% |
| Revenue CAGR 5y | 97.06% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 1.1x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
APLS leads on
- Revenue CAGR 5y97.06%vs 12.75%+87%
- Market cap$5.25Bvs $2.23B+57%
- ROIC (TTM)18.11%vs 9.43%+48%
- Gross margin90.12%vs 72.39%+20%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- EV/EBIT36.6xvs 96.0x+62%
- Debt / Equity0.5xvs 1.1x+59%
- Net margin24.35%vs 12.06%+50%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.